not, plead an antitrust injury causally linked to Andrx’s alleged anticom-petitive behavior. Andrx Pharm., Inc. v. Friedman, 83 F.Supp.2d 179, 185-87 (D.D.C.2000) (“Court cannot find that Bio-vail can establish that it has suffered ‘antitrust injury.’ ”). On February 2, 2000 Bio-vail moved for reconsideration under FRCP 60(b) and on February 4, 2000 it filed a notice of appeal (No. 00-5050). The district court subsequently denied the motion for reconsideration and Biovail noticed its appeal of that decision (No. 00-5396) on November 3, 2000. This court granted Biovail’s motion to consolidate the appeals. III. Analysis We give de novo review to a Rule 12(b)(6) dismissal. See NRA v. Reno, 216 F.3d 122, 126 (D.C.Cir.2000); see also Amarel v. Connell, 102 F.3d 1494, 1507 (9th Cir.1997) (<HOLDING>). “The complaint should not be dismissed unless
holding that antitrust standing is question of law reviewed de novo holding that whether consent was valid under the fourth amendment is a question of law to be reviewed de novo holding that the threshold question of whether to adopt a doctrine is reviewed de novo holding the ultimate question of probable cause should be reviewed de novo holding question of law applied to undisputed facts reviewed de novo